Is Regeneron Pharmaceuticals Shares Lagging Behind the Nasdaq?

Overview of Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology firm based in Tarrytown, New York, boasting a market capitalization of approximately $82.6 billion. The company is dedicated to the research, development, production, and distribution of groundbreaking treatments for a wide array of serious medical conditions. Their expertise spans areas such as ophthalmology, allergy and inflammation, oncology, cardiovascular and neurological disorders, infectious diseases, hematology, and rare diseases.

Market Position and Reputation

With a market cap well above $10 billion, Regeneron is firmly established as a large-cap stock. The company is highly regarded for its extensive lineup of innovative therapies and its role in advancing new medical solutions.

Latest Headlines from Barchart

Recent Stock Performance

Regeneron’s share price has dipped just 4.8% from its 52-week peak of $821.11, which was set on January 9. Over the last quarter, REGN experienced a slight decrease, while the broader Nasdaq Composite ($NASX) fell by 2.4% during the same period.

Looking at the past year, REGN’s stock has risen by 11.2%, trailing behind the NASX’s 22.2% gain. However, since the start of the year, Regeneron has advanced 1.3%, outperforming the NASX, which declined by 2.5%.

Since mid-July 2025, REGN has generally remained above its 50-day moving average, despite some volatility. The stock has also consistently traded above its 200-day moving average since late October.

Factors Influencing Stock Growth

The upward momentum in Regeneron’s stock price can be attributed to favorable regulatory outcomes, progress in its drug pipeline, and strong investor confidence. Notably, the company has reached new highs amid enthusiasm for FDA approvals and expanded indications for flagship products like Eylea HD, as well as sustained sales growth for Dupixent and Libtayo.

Comparative Performance and Analyst Outlook

Despite these achievements, REGN has lagged behind competitor Amgen Inc. (AMGN), which posted a 26.9% increase over the past year and an 18.6% gain year-to-date.

Nevertheless, market analysts remain highly positive about Regeneron’s future. Among the 27 analysts covering the stock, the consensus is a “Strong Buy,” with an average price target of $870.35—representing an 11.3% upside from current levels.